Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2017
Illumina, Inc.
(Exact name of registrant as specified in its charter)
001-35406
(Commission File Number)
|
| | |
| | |
| | |
Delaware | | 33-0804655 |
(State or other jurisdiction of incorporation) | | (I.R.S. Employer Identification No.) |
5200 Illumina Way, San Diego, CA 92122
(Address of principal executive offices) (Zip code)
(858) 202-4500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 13, 2017, Illumina, Inc. provided updated release dates for the family of NovaSeq products. Given customer feedback since launch, NovaSeq’s S1 and S4 flow cells have been prioritized and are expected to be available for shipment in the third quarter of 2017. The NovaSeq 5000 System and S3 flow cells are expected to be available for shipment in early 2018 and the NovaSeq 6000 System and S2 flow cells remain on track for shipment late in the first quarter of this year.
Forward-Looking Statements
This Form 8-K contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the shipment dates of NovaSeq products. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to manufacture robust instrumentation and consumables and (ii) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | |
| | | | |
| | ILLUMINA, INC. |
Date: | February 13, 2017 | By: | /s/ SAM A. SAMAD |
| | | Sam A. Samad |
| | | Senior Vice President and Chief Financial Officer |